At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 250 enrolled
Drug / intervention
ticagrelordrug
Likely dose
ticagrelor 360mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Trial of Different Loading Dose of Ticagrelor for Antiplatelet Effect in Patients With Non -ST-segment Elevation ACS Undergoing Percutaneous Coronary Intervention
General Hospital of Chinese Armed Police Forces·interventional·Posted Oct 14, 2013·Updated Nov 9, 2016
In Brief
A Phase 4 clinical trial evaluating ticagrelor for Non ST Segment Elevation Acute Coronary Syndrome. Completed, enrolled 250 participants across 2 sites.
Detailed Summary
It is designed to test the hypothesis that high loading dose(360mg) ticagrelor versus conventional loading dose(180mg) will result in a higher inhibition of platelet aggregation(IPA) without increasing the bleeding events.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 2013
Enrollment StartJun 2014
Primary CompletionDec 2015
TodayJul 2026
First PostedOct 14, 2013
Enrollment StartJun 1, 2014
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 12.7 years ago
Interventions
ticagrelordrug
Patients will receive ticagrelor 360mg loading dose or 180mg loading dose , then 90mg bid maintenance dose starting 12 hours after loading dose.